Nutex Health Q1 Earnings Call Highlights

Key Points

• Mixed Q1 results: Total revenue rose to $216.5 million (up 2% y/y) and net income jumped to $46.8 million, but Adjusted EBITDA fell 21% to $57.6 million and gross margins compressed materially vs. year-ago levels.
• IDR/arbitration dynamics: Nutex submits about 50–60% of claims to IDR, prevails in over 85% of determinations with collection rates >80%, but recorded unusually high arbitration costs (~35% of arbitration revenue) in Q1 that management expects to normalize toward ~24–26% through the year.
• Strategic shift and balance sheet moves: The board approved direct investment in developing new hospitals (three Florida projects started, typically $20–30M and 18–24 months to build) with plans to monetize via sale-leasebacks; Nutex completed a $25M buyback, launched a second $25M program, and ended the quarter with cash of $207.3 million and net long-term debt of $24.3 million.

Nutex Health NASDAQ: NUTX reported first-quarter 2026 revenue growth and a sharp increase in net income, while management emphasized ongoing investments in operational infrastructure, a growing pipeline of new facilities, and a shift toward internally funding certain de novo hospital developments.

First-quarter results: revenue up, net income jumps

Chairman and CEO Dr. Tom Vo said total revenue rose to $216.5 million, up 2% from $211.8 million in the year-ago quarter. Net income increased to $46.8 million from $21.2 million in Q1 2025.

Adjusted EBITDA declined to $57.6 million, down 21% year over year. Vo attributed the decline to the “timing of recognition for IDR expenses” when comparing Q1 2025 to Q1 2026.

Chief Financial Officer Jon Bates said hospital division revenue increased to $207.6 million from $203.9 million, while the population health division posted revenue of $8.9 million, up about 14% from $7.8 million a year earlier.

Patient volumes rise, with “same hospital” tracking

On volumes, Vo said total patient visits reached 49.7 thousand, up 3.1% from 48.3 thousand in Q1 2025. He added that 0.6% of the growth came from “same hospitals” and noted that this year’s flu season was “much milder” than 2025’s.

Bates said the company will begin using “same hospital” analytics more prominently, defining it as hospitals “fully opened in both periods presented.” For the current comparison, he said the same-hospital set consisted of facilities “fully opened by December 31st of 2024.” He reported same-hospital revenue growth of 0.2% and same-hospital visit growth of 0.6% for the quarter.

In the Q&A, Vo addressed an analyst question about why total volume growth appeared modest given new openings. He said two hospitals opened in late December 2025 and one opened in January, adding that they are still ramping. He also again cited the lighter flu season as a factor.

IDR and arbitration: submissions, win rates, and cost dynamics

Management discussed ongoing use of the Independent Dispute Resolution (IDR) process. Bates said Nutex continues to submit about 50% to 60% of claims through IDR. He added that the company currently prevails in “over 85%” of determinations and has an average collection rate of “over 80%” on those wins.

Bates also provided details on arbitration costs and accounting treatment. Facility-level operating costs increased during the quarter, and Bates said $19.8 million of a $31.3 million increase in facility-level operating costs was related to arbitration costs tied to additional arbitration revenue recorded in the period. He said the company anticipates arbitration costs ultimately settling around 24% to 26% of overall arbitration-related revenue realized.

However, he noted that during Q1 2026 arbitration costs were higher—about 35% of arbitration-related revenue—because Nutex records 100% of anticipated arbitration costs, while revenue is recorded based on its collection rate. In response to an analyst question, Bates said he expects the cost percentage to “work its way back” toward historical levels over the second, third, and fourth quarters.

On payer negotiations and the contracting environment, Vo said the company is “always trying to get in-network if possible” and is reviewing new offers. He referenced “three very positive court cases” in California, Florida, and Pennsylvania that he characterized as favorable to providers, while also calling the situation a “continuing process” as insurers “are always trying to fight back.”

Margins, expenses, stock-based comp, and taxes

Bates said gross profit was $91.7 million, or 42.4% of revenue, compared with $118.3 million, or 55.9%, in Q1 2025. General and administrative expense rose to 6.6% of revenue (or $14.4 million) from 4.7% (or $10 million) in the year-ago period. Operating income was $81.3 million, up slightly from $80.7 million.

The CFO also highlighted a swing in stock compensation. Total stock compensation for the quarter was a $3.9 million gain, compared with a $27.6 million expense in Q1 2025. Bates explained in Q&A that stock-based compensation moves with earn-out calculations tied to facility performance and share price, and that one hospital earn-out finalized on March 31, 2026, with two more facilities still in measurement periods through the fourth quarter of 2026.

Asked about the effective tax rate for the rest of the year, Bates said Q1’s rate was “more representative” of what he would expect going forward, estimating an effective rate in the “high teens to 20%.”

Balance sheet, repurchases, and development strategy shift

Vo and Bates described a strong balance sheet and share repurchase activity. Vo said net long-term debt fell to $24.3 million at the end of Q1 2026 from $29.2 million at year-end 2025, and cash on hand increased to $207.3 million from $185.6 million. Bates added that net cash from operating activities rose to $75.5 million from $51 million a year earlier, and accounts receivable increased to $339.6 million from $319.4 million.

Vo said Nutex completed its inaugural $25 million share repurchase program during the quarter, retiring approximately 119,000 shares, and initiated a second $25 million program.

A major strategic development discussed on the call was the board’s approval for Nutex to begin directly investing in the development and construction of new hospital facilities, rather than relying solely on third-party developers alongside physician partners. Vo said Nutex does not intend to hold real estate assets long term, and instead expects to monetize completed or stabilized facilities through sale-leaseback transactions with third-party owners such as REITs, though he said a specific REIT partner has not yet been identified.

In Q&A, Vo said the process “has already started” with three new projects in Florida, and estimated that projects typically take 18 to 24 months to develop and open. He said each project costs roughly $20 million to $30 million to build, and described an approach where Nutex invests down payments, secures financing, and later “flip[s] it to a REIT” after opening. Bates added that during development, the balance sheet would reflect “the land and the building” along with “a mortgage of some kind.”

Vo also provided an update on the company’s footprint and planned openings. He said Nutex operates 27 hospital facilities across 12 states and remains on track to open three additional hospitals in the third and fourth quarters of 2026 in:

• San Antonio, Texas
• Jacksonville, Florida
• West Little Rock, Arkansas

Operationally, Chief Operating Officer Wesley Bamburg said the company is working to improve patient acuity and increase the mix of observation and inpatient patients, while making targeted staffing and technology investments. He said labor costs rose to $41.4 million, about 19.1% of net revenue, reflecting staffing decisions tied to demand and higher acuity. Bamburg also said the company received more than 2,400 patient reviews during the quarter and averaged a 4.8 out of 5 Google rating.

On the population health side, President Dr. Warren Hosseinion said the division oversees “almost 40,000 patients” across Medicare Advantage, commercial, and Medicaid managed care. He described a strategy centered on building IPA networks around Nutex facilities, offering physicians ownership opportunities, hospital privileges, and incentives tied to quality metrics. In Q&A, Hosseinion said Nutex’s IPAs in Southern California, Houston, and Southern Florida generated cash on a standalone basis in 2025, while emphasizing the company’s goal is not to build “the largest IPA” but to increase awareness and drive both IPA and non-IPA volume to Nutex hospitals.

About Nutex Health NASDAQ: NUTX

Nutex Health, Inc NASDAQ: NUTX is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.